The Effects of Ceruletide in Schizophrenia

Daniel W. Hommer, David Pickar, Alec Roy, Philip Ninan, John Boronow, Steven M. Paul

Research output: Contribution to journalArticle

Abstract

Eight neuroleptic-resistant schizophrenic patients were treated with ceruletide diethylamine, a cholecystokininlike peptide, in a placebo-controlled, double-blind, cross-over study. Ceruletide or placebo was administered intramuscularly twice a day for four consecutive days while patients received a constant dose of fluphenazine hydrochloride. Cholecystokinin octapeptide was also administered to four different schizophrenic patients in a double-blind, cross-over study. Cholecystokinin or placebo was administered as a slow intravenous infusion daily for four days. There were no changes in either the positive or negative symptoms of schizophrenia between the periods of placebo, ceruletide, or cholecystokinin administration. Furthermore, there was no tendency for the patients' conditions to either improve or worsen during the course of ceruletide or cholecystokinin treatment. In contrast to previous reports from uncontrolled studies, cholecystokininlike peptides appear to be devoid of antipsychotic properties when administered parenterally.

Original languageEnglish (US)
Pages (from-to)617-619
Number of pages3
JournalArchives of General Psychiatry
Volume41
Issue number6
DOIs
StatePublished - 1984
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Hommer, D. W., Pickar, D., Roy, A., Ninan, P., Boronow, J., & Paul, S. M. (1984). The Effects of Ceruletide in Schizophrenia. Archives of General Psychiatry, 41(6), 617-619. https://doi.org/10.1001/archpsyc.1984.01790170091010